APN-01 is under clinical development by APEIRON Biologics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect APN-01’s likelihood of approval (LoA) and phase transition for Pulmonary Arterial Hypertension took place on 11 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their APN-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

APN-01 overview

APN-01 is under development for the treatment of acute lung injury, acute respiratory distress syndrome, pulmonary arterial hypertension and Coronavirus infection (COVID-19). It is administered intravenously as a solution. The drug candidate is a recombinant human angiotensin converting enzyme 2 (rhACE2).

APEIRON Biologics overview

APEIRON Biologics (APEIRON) is a clinical-stage biotechnology company that concentrates on the development of biological and immunological solutions for the treatment of various cancers. The company’s pipeline products include APN01, APN301, APN311, APN401, APN411, APN421 and APN431. Its APN311 is an antibody-based therapy used for the treatment of high-risk neuroblastoma. APEIRON’s APN301 is an anti-GD2 antibody-IL2 fusion protein used for intratumoral application in GD2+ pediatric cancers. The company carries out projects in the biotherapy and cancer immune field. APEIRON is headquartered in Vienna, Austria.

Quick View APN-01 LOA Data

Report Segments
  • Innovator
Drug Name
  • APN-01
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Infectious Disease
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.